FDA granted priority review to Lonsurf (trifluridine/tipiracil) as monotherapy or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and, if RAS wild-type, an anti-EGFR therapy.
New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that one’s biological age, which can be higher than his or her chronological age – a concept called accelerated aging – may predict who’s at risk for developing colon polyps, a known risk factor for colorectal cancer.
